Drugs Affecting Blood and Blood Formation Practice Questions

Q: Tranexamic acid is a specific antidote of which class of drugs?

Fibrinolytic drugs. **Explanation:** **1. Why Fibrinolytic drugs is correct:** Tranexamic acid (TXA) is a **synthetic derivative of the amino acid lysine**. It acts as a competitive inhibitor of plasminogen activation. Fibrinolytic drugs (like Streptokinase or Alteplase) work by converting plasminogen to plasmin, which degrades fibrin clots. TXA binds to the lysine-binding sites on plasminogen molecules, preventing them from binding to fibrin. This effectively blocks the action of plasmin and inhibits fibrinolysis. Therefore, it is the specific antidote used to manage bleeding complications induced by fibrinolytic overdose. **2. Why the other options are incorrect:** * **Heparin:** The specific antidote for heparin overdose is **Protamine sulfate**, which neutralizes heparin through a chemical (ionic) antagonism. * **Barbiturates:** There is no specific pharmacological antidote for barbiturates. Management is primarily supportive (alkalinization of urine for phenobarbital and gastric lavage). * **Organophosphates:** The specific antidotes are **Atropine** (to block muscarinic effects) and **Pralidoxime/2-PAM** (to reactivate acetylcholinesterase). **3. NEET-PG High-Yield Pearls:** * **Mechanism:** TXA is an **antifibrinolytic**. It does not promote clotting but prevents the breakdown of existing clots. * **Clinical Uses:** Beyond fibrinolytic reversal, it is high-yield for **Menorrhagia**, **Post-partum hemorrhage (PPH)**, and trauma-induced bleeding (CRASH-2 trial). * **Contraindication:** It should be avoided in patients with active intravascular clotting (e.g., DVT or PE) due to the risk of stabilizing pathological thrombi. * **Alternative:** **Epsilon-aminocaproic acid (EACA)** is another antifibrinolytic with a similar mechanism but is less potent than TXA.

Q: Platelet aggregation is inhibited by all agents except?

Thromboxane A2. **Explanation:** The question asks for the agent that does **not** inhibit platelet aggregation. To answer this, one must distinguish between antiplatelet drugs and physiological platelet activators. **Why Thromboxane A2 (TXA2) is the correct answer:** TXA2 is a potent **platelet agonist** and vasoconstrictor produced by activated platelets via the cyclooxygenase-1 (COX-1) pathway. It binds to TP receptors on the platelet surface, leading to a conformational change in the GP IIb/IIIa receptors, which promotes platelet aggregation. Therefore, TXA2 **promotes** rather than inhibits aggregation. **Analysis of Incorrect Options:** * **Aspirin:** It is an irreversible inhibitor of the **COX-1 enzyme**. By blocking COX-1, it prevents the synthesis of TXA2, thereby inhibiting platelet aggregation for the lifespan of the platelet (7–10 days). * **Clopidogrel:** This is a P2Y12 receptor antagonist. It prevents **ADP (Adenosine Diphosphate)** from binding to its receptor on platelets, which is a crucial step in platelet activation and subsequent aggregation. * **Eptifibatide:** This is a **GP IIb/IIIa receptor antagonist**. Since GP IIb/IIIa is the "final common pathway" for platelet aggregation (where fibrinogen binds to link platelets), blocking it provides potent inhibition of aggregation. **High-Yield Clinical Pearls for NEET-PG:** * **Final Common Pathway:** GP IIb/IIIa receptor (Inhibitors: Abciximab, Eptifibatide, Tirofiban). * **Phosphodiesterase Inhibitors:** Dipyridamole and Cilostazol also inhibit aggregation by increasing intra-platelet cAMP levels. * **P2Y12 Inhibitors:** Clopidogrel and Prasugrel are prodrugs (irreversible), while **Ticagrelor** is a direct-acting drug (reversible). * **Prostacyclin (PGI2):** Unlike TXA2, PGI2 is a potent endogenous **inhibitor** of platelet aggregation produced by vascular endothelium.

Q: Macrocytic anemia is caused by all EXCEPT:

Pentamidine. **Explanation:** The core concept behind this question is the inhibition of **Dihydrofolate Reductase (DHFR)**, an enzyme essential for converting dihydrofolate into tetrahydrofolate. Tetrahydrofolate is a critical cofactor for DNA synthesis; its deficiency leads to impaired nuclear maturation while the cytoplasm continues to grow, resulting in **megaloblastic (macrocytic) anemia**. **Why Pentamidine is the Correct Answer:** Pentamidine is an antiprotozoal agent used primarily for *Pneumocystis jirovecii* and Leishmaniasis. Its mechanism involves interfering with oxidative phosphorylation and DNA synthesis by binding to the minor groove of DNA. Crucially, **Pentamidine does not inhibit the folate pathway** or DHFR. Therefore, it does not cause macrocytic anemia. Its primary toxicities include nephrotoxicity, hypoglycemia/diabetes, and hypotension. **Analysis of Incorrect Options:** * **Pyrimethamine:** An antiprotozoal (used in Toxoplasmosis) that selectively inhibits protozoal DHFR. At high doses, it can cross-react with human DHFR, leading to folate deficiency. * **Methotrexate:** A potent inhibitor of human DHFR used in chemotherapy and autoimmune diseases. It is a classic cause of drug-induced megaloblastic anemia. * **Trimethoprim:** An antibacterial that inhibits bacterial DHFR. Similar to pyrimethamine, prolonged or high-dose use can affect human DHFR, especially in patients with borderline folate stores. **High-Yield Clinical Pearls for NEET-PG:** * **Rescue Therapy:** To prevent macrocytic anemia caused by DHFR inhibitors (like Methotrexate), **Leucovorin (Folinic acid)** is administered. It bypasses the blocked DHFR enzyme. * **Other Drugs causing Macrocytosis:** Phenytoin (interferes with absorption), Zidovudine (AZT), and Hydroxyurea. * **Mnemonic:** Drugs acting on DHFR = **"M-P-T"** (Methotrexate, Pyrimethamine, Trimethoprim).

Q: What is the mechanism of action of Rivaroxaban?

Direct factor Xa inhibitor. **Explanation:** **1. Mechanism of the Correct Answer (Option A):** Rivaroxaban is a **Direct Oral Anticoagulant (DOAC)** that acts as a potent, highly selective, and **direct inhibitor of Factor Xa**. Factor Xa is the "nexus" of the coagulation cascade where the intrinsic and extrinsic pathways converge to form the common pathway. By binding directly to the active site of both free and clot-bound Factor Xa, Rivaroxaban prevents the conversion of prothrombin (Factor II) to thrombin (Factor IIa), thereby inhibiting fibrin clot formation. **2. Analysis of Incorrect Options:** * **Option B (Activated factor VIIa):** This is a pro-coagulant (e.g., Eptacog alfa) used to treat bleeding episodes in patients with hemophilia or Factor VII deficiency. It promotes clotting rather than inhibiting it. * **Option C (Vitamin K antagonist):** This describes the mechanism of **Warfarin**. Warfarin acts by inhibiting the enzyme Vitamin K Epoxide Reductase (VKOR), preventing the γ-carboxylation of Factors II, VII, IX, and X. Unlike Rivaroxaban, Warfarin has a slow onset and requires INR monitoring. **3. High-Yield NEET-PG Clinical Pearls:** * **The "-xaban" Suffix:** Remember that drugs with **"xa"** in their name (Rivaroxaban, Apixaban, Edoxaban) target Factor **Xa**. * **Advantages:** Unlike Warfarin, Rivaroxaban has a rapid onset, predictable pharmacokinetics (no routine monitoring required), and fewer drug-food interactions. * **Reversal Agent:** The specific antidote for Rivaroxaban and Apixaban is **Andexanet alfa**. * **Clinical Use:** It is a first-line choice for stroke prevention in non-valvular atrial fibrillation and the treatment/prophylaxis of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE).

Q: Heparin inhibits the active form of the following coagulation factors except:

Factor V. The mechanism of action of **Unfractionated Heparin (UFH)** depends on its binding to **Antithrombin III (AT-III)** [2]. This binding induces a conformational change in AT-III, converting it from a slow to a rapid inhibitor of serine protease coagulation factors [3]. 1. **Why Factor V is the correct answer:** Heparin (via AT-III) specifically targets **serine proteases**. Coagulation factors are categorized into serine proteases (II, VII, IX, X, XI, XII) and **cofactors (V and VIII)** [4]. Since Factor V is a cofactor and not a protease, it is not directly inhibited by the Heparin-AT-III complex [4]. 2. **Why the other options are incorrect:** * **Factor X (Option B):** Heparin significantly accelerates the inhibition of Factor Xa [2]. Low Molecular Weight Heparin (LMWH) acts almost exclusively on Factor Xa [1]. * **Factor XI and XII (Options C & D):** These are part of the intrinsic pathway and are serine proteases. Heparin inhibits the active forms of factors XIIa, XIa, IXa, and IIa (Thrombin) [4]. **High-Yield Clinical Pearls for NEET-PG:** * **Monitoring:** The efficacy of UFH is monitored using **aPTT** (intrinsic pathway), whereas LMWH does not require routine monitoring (but can be checked via Anti-Xa levels). * **Antidote:** **Protamine sulfate** is the specific antidote for heparin overdose (1 mg neutralizes ~100 units of heparin) [1]. * **Side Effects:** The most unique side effect is **Heparin-Induced Thrombocytopenia (HIT)**, caused by IgG antibodies against the Heparin-Platelet Factor 4 (PF4) complex [1]. * **Safe in Pregnancy:** Heparin does not cross the placenta, making it the anticoagulant of choice during pregnancy.

Q: What is the best drug for thrombolysis and reperfusion in acute myocardial infarction?

Tissue plasminogen activator. **Explanation:** The correct answer is **Tissue plasminogen activator (tPA)**, such as Alteplase, Reteplase, or Tenecteplase. **Why tPA is the best choice:** The primary goal in acute myocardial infarction (AMI) is rapid reperfusion. tPA is a **clot-specific (fibrin-selective)** plasminogen activator. It preferentially activates plasminogen that is already bound to fibrin within a thrombus, rather than circulating plasminogen. This leads to more effective clot lysis and a lower risk of systemic lytic states compared to non-selective agents. Clinical trials (like GUSTO-1) have demonstrated that tPA provides superior 90-minute patency rates of the infarct-related artery and better survival outcomes. **Why other options are incorrect:** * **Streptokinase (A):** It is a non-fibrin-selective agent derived from beta-hemolytic streptococci. It is antigenic (can cause anaphylaxis) and causes systemic depletion of fibrinogen, increasing bleeding risks. It is less effective at achieving rapid reperfusion than tPA. * **Urokinase (B):** Primarily used for pulmonary embolism or peripheral arterial occlusion. It is non-selective and lacks the high affinity for fibrin required for optimal AMI management. * **Anistreplase (D):** A complex of streptokinase and plasminogen. While it has a longer half-life, it is non-selective and carries the same allergic risks as streptokinase. **High-Yield NEET-PG Pearls:** * **Tenecteplase** is currently the preferred tPA because it has the highest fibrin specificity and can be given as a **single IV bolus**, making it ideal for pre-hospital thrombolysis. * **Time is Muscle:** Thrombolytics are most effective if given within the "Golden Hour" (first 60 mins) and generally indicated within 12 hours of symptom onset if Primary PCI is unavailable. * **Absolute Contraindications:** Previous hemorrhagic stroke, ischemic stroke within 3 months, active internal bleeding, or suspected aortic dissection.

Q: Danaparoid is:

A parenteral Xa inhibitor. **Explanation:** **Danaparoid** is a heparinoid mixture consisting of heparan sulfate, dermatan sulfate, and chondroitin sulfate. Its primary mechanism of action is the **indirect inhibition of Factor Xa** by enhancing the activity of antithrombin III. 1. **Why Option C is Correct:** Danaparoid is administered via **parenteral routes** (subcutaneous or intravenous). It has a high anti-Xa to anti-IIa ratio (approximately 20:1), making it a potent and selective Factor Xa inhibitor. Its clinical hallmark is its lack of cross-reactivity with heparin-induced antibodies, making it a first-line alternative for patients with **Heparin-Induced Thrombocytopenia (HIT)**. 2. **Why Other Options are Incorrect:** * **Option A:** It is not an "analog" of Factor Xa; it is an inhibitor of its activity. * **Option B:** Oral Xa inhibitors (Rivaroxaban, Apixaban, Edoxaban) belong to the DOAC (Direct Oral Anticoagulant) class and act directly on Xa without requiring antithrombin. * **Option D:** Oral direct thrombin inhibitors (e.g., Dabigatran) act on Factor IIa. Danaparoid has minimal effect on thrombin (IIa). **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Danaparoid is frequently tested as a safe alternative for anticoagulation in **HIT** and in pregnant patients who develop HIT (as it does not cross the placenta). * **Monitoring:** Unlike Heparin, it does not significantly prolong aPTT. Monitoring is done using **anti-Xa assays** if necessary. * **Half-life:** It has a long half-life (~24 hours), which is significantly longer than LMWH.

Question 1

Tranexamic acid is a specific antidote of which class of drugs?

Accepted Answer

Fibrinolytic drugs

Answer

Heparin

Answer

Barbiturates

Answer

Organophosphates

Question 2

All of the following are true about Heparin except?

Accepted Answer

Heparin can lead to arterial thrombosis more than venous thrombosis.

Answer

Argatroban is the drug of choice for Heparin-induced thrombocytopenia.

Answer

Unfractionated Heparin induces antibodies against PF4 and leads to platelet aggregation.

Answer

Unfractionated Heparin is safer in renal failure.

Question 3

Platelet aggregation is inhibited by all agents except?

Accepted Answer

Thromboxane A2

Answer

Aspirin

Answer

Clopidogrel

Answer

Eptifibatide

Question 4

Macrocytic anemia is caused by all EXCEPT:

Accepted Answer

Pentamidine

Answer

Pyrimethamine

Answer

Methotrexate

Answer

Trimethoprim

Question 5

Heparin is contraindicated in patients suffering from which of the following conditions?

Accepted Answer

Bleeding due to defibrination syndrome

Answer

Pulmonary tuberculosis

Answer

Subacute bacterial endocarditis

Answer

Large malignant tumours

Question 6

What is the mechanism of action of Rivaroxaban?

Accepted Answer

Direct factor Xa inhibitor

Answer

Activated factor VIIa

Answer

Vitamin K antagonist

Answer

None of the above

Question 7

Heparin inhibits the active form of the following coagulation factors except:

Accepted Answer

Factor V

Answer

Factor X

Answer

Factor XI

Answer

Factor XII

Question 8

Which of the following statements about oral anticoagulants is FALSE?

Accepted Answer

They act both in vivo and in vitro.

Answer

They act in vivo.

Answer

They interfere with the synthesis of Vitamin K.

Answer

They can cause hematuria.

Question 9

What is the best drug for thrombolysis and reperfusion in acute myocardial infarction?

Accepted Answer

Tissue plasminogen activator

Answer

Streptokinase

Answer

Urokinase

Answer

Anistreplase

Question 10

Danaparoid is:

Accepted Answer

A parenteral Xa inhibitor

Answer

An Xa analog

Answer

An oral Xa inhibitor

Answer

An oral direct thrombin inhibitor

Drugs Affecting Blood and Blood Formation — MCQs

Drugs Affecting Blood and Blood Formation — MCQs

On this page

Practice by Chapter

Want unlimited practice?